25 July 2025
EMA: First reformulation of an inhaled medicine with environmentally friendly gas propellant
The European Medicines Agency (EMA) has recommended a change in the composition of Trixeo Aerosphere and its duplicate product Riltrava Aerosphere, which ought to replace existing gas propellant with a low global warming potential (GWP) gas alternative. This alternative has a 1000-fold reduction in GWP, but similar physical properties as the current propellant.
Trixeo Aerosphere and Riltrava Aerosphere are the first of their kind to have a gas propellant with low GWP. This switch is part of the EU Regulation on fluorinated greenhouse gases (EU Regulation 2024/573), with the goal of phasing out high GWP gases for environmental reasons.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting